About Pricing FAQs Providers Trials Blog

Back to your record

Login Get started

Finding studies

Your health journey, clearly organized.

Questions? feedback@clareohealth.com

Product

How it works
Pricing
For Providers
Trials

Company

About
Blog
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Non-expensive and Widely Available Tests as Diagnostic Tools in Dementia and Their Ability to Predict Disease Progression

NCT01642420·1 site·ClinicalTrials.gov

What this study is about

Take this into the appointment.

Saves the questions and what to expect into your notes, next to the visit they belong to.

Keep this study

Malene s Nielsen, MD
CONTACT
0045 2868 0034 malni@regionsjaelland.dk
Peter Høgh, MD, Ph.D
CONTACT
0045 4732 2809 phh@regionsjaelland.dk

Lead

Zealand University Hospital

With

Copenhagen University Hospital, Rigshospitalet

Age

50–90

Sex

ALL

Healthy volunteers

Accepted

You may be eligible if

For patients:
age 50 to 90
diagnosed with MCI or AD
cerebrospinal fluid examination and EEG performed at baseline
For control persons:
age 50 to 90
MMSE score equal or above 26
ACE score equal or above 85
Normal physical examination, including normal blood samples, CT of cerebrum and EEG examination

You may not be if

Pregnant or breastfeeding
psychiatric disease, former depression is allowed if antidepressive treatment has been initiated of a leat 3 months duration
Neurologic or somatic disease, including former severe head trauma or neuroinfection
Antipsychotic treatment
Former severe abuse of alcohol, medication or drugs
ECT treatment or anaesthesia within the last 3 months
no closely related person to assist the patient
meet the diagnostic criteria for MCI or AD

The record

StatusUnknown

PhaseNo phase

Taking part115

StartedApr 2012

UpdatedSep 13, 2012

Conditions

Alzheimers Disease Mild Cognitive Impairment

Where1

Neurologisk Afd, Roskilde Sygehus
Roskilde, Denmark